Impact of the motor complications of Parkinson's disease on the quality of life.
Identifieur interne : 000F59 ( Ncbi/Merge ); précédent : 000F58; suivant : 000F60Impact of the motor complications of Parkinson's disease on the quality of life.
Auteurs : Stéphane Chapuis [France] ; Lemlih Ouchchane ; Olivier Metz ; Laurent Gerbaud ; Franck DurifSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2005.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antiparkinson Agents (adverse effects), Dyskinesia, Drug-Induced (physiopathology), Female, Follow-Up Studies, Health Status Indicators, Humans, Levodopa (adverse effects), Male, Middle Aged, Movement Disorders (etiology), Movement Disorders (psychology), Neurologic Examination, Parkinson Disease (physiopathology), Parkinson Disease (psychology), Psychiatric Status Rating Scales, Quality of Life, Questionnaires, Retrospective Studies.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- etiology : Movement Disorders.
- physiopathology : Dyskinesia, Drug-Induced, Parkinson Disease.
- psychology : Movement Disorders, Parkinson Disease.
- Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Health Status Indicators, Humans, Male, Middle Aged, Neurologic Examination, Psychiatric Status Rating Scales, Quality of Life, Questionnaires, Retrospective Studies.
Abstract
The impact of motor complications of Parkinson's disease (PD), especially levodopa-induced dyskinesias, on quality of life (QL) was studied in 143 patients with PD. All were evaluated on the Hoehn and Yahr (H&Y) scale, and the Motor part of the Unified Parkinson's Disease Rating Scale (UPDRS). Motor complications were analyzed using the UPDRS Parts IV(A) and IV(B) and the Abnormal Involuntary Movement Scale. A specific Parkinson's disease quality of life questionnaire (39-item version, PDQ-39) was used. Motor complications significantly worsened the PDQ-39 Summary Index (PDQ-SI) of patients with PD. The dimensions of Mobility, Activities of Daily Living, Stigma, and Communication were the most strongly affected. "Peak dose" dyskinesia decreased Mobility, Emotional Well-Being, and Cognition, whereas biphasic dyskinesia affected Mobility, Stigma, Communication, and Activities of Daily Living. Morning akinesia, end-of-dose fluctuations, and "unpredictable offs" decreased QL on the dimensions of Mobility, Activities of Daily Living, Stigma, and Communication. Nocturnal akinesia led to a deterioration of all dimensions of the PDQ-39. Thus, motor complications and especially nocturnal akinesia and biphasic dyskinesias worsened the QL of PD patients.
DOI: 10.1002/mds.20279
PubMed: 15384126
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003329
- to stream PubMed, to step Curation: 003329
- to stream PubMed, to step Checkpoint: 003100
Links to Exploration step
pubmed:15384126Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of the motor complications of Parkinson's disease on the quality of life.</title><author><name sortKey="Chapuis, Stephane" sort="Chapuis, Stephane" uniqKey="Chapuis S" first="Stéphane" last="Chapuis">Stéphane Chapuis</name><affiliation wicri:level="1"><nlm:affiliation>Service de Neurologie, Centre Hospitalier Vichy, France. stephane.chapuis@ch-vichy.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Neurologie, Centre Hospitalier Vichy</wicri:regionArea><wicri:noRegion>Centre Hospitalier Vichy</wicri:noRegion><wicri:noRegion>Centre Hospitalier Vichy</wicri:noRegion></affiliation></author><author><name sortKey="Ouchchane, Lemlih" sort="Ouchchane, Lemlih" uniqKey="Ouchchane L" first="Lemlih" last="Ouchchane">Lemlih Ouchchane</name></author><author><name sortKey="Metz, Olivier" sort="Metz, Olivier" uniqKey="Metz O" first="Olivier" last="Metz">Olivier Metz</name></author><author><name sortKey="Gerbaud, Laurent" sort="Gerbaud, Laurent" uniqKey="Gerbaud L" first="Laurent" last="Gerbaud">Laurent Gerbaud</name></author><author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15384126</idno><idno type="pmid">15384126</idno><idno type="doi">10.1002/mds.20279</idno><idno type="wicri:Area/PubMed/Corpus">003329</idno><idno type="wicri:Area/PubMed/Curation">003329</idno><idno type="wicri:Area/PubMed/Checkpoint">003100</idno><idno type="wicri:Area/Ncbi/Merge">000F59</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of the motor complications of Parkinson's disease on the quality of life.</title><author><name sortKey="Chapuis, Stephane" sort="Chapuis, Stephane" uniqKey="Chapuis S" first="Stéphane" last="Chapuis">Stéphane Chapuis</name><affiliation wicri:level="1"><nlm:affiliation>Service de Neurologie, Centre Hospitalier Vichy, France. stephane.chapuis@ch-vichy.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Neurologie, Centre Hospitalier Vichy</wicri:regionArea><wicri:noRegion>Centre Hospitalier Vichy</wicri:noRegion><wicri:noRegion>Centre Hospitalier Vichy</wicri:noRegion></affiliation></author><author><name sortKey="Ouchchane, Lemlih" sort="Ouchchane, Lemlih" uniqKey="Ouchchane L" first="Lemlih" last="Ouchchane">Lemlih Ouchchane</name></author><author><name sortKey="Metz, Olivier" sort="Metz, Olivier" uniqKey="Metz O" first="Olivier" last="Metz">Olivier Metz</name></author><author><name sortKey="Gerbaud, Laurent" sort="Gerbaud, Laurent" uniqKey="Gerbaud L" first="Laurent" last="Gerbaud">Laurent Gerbaud</name></author><author><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (adverse effects)</term><term>Dyskinesia, Drug-Induced (physiopathology)</term><term>Female</term><term>Follow-Up Studies</term><term>Health Status Indicators</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Male</term><term>Middle Aged</term><term>Movement Disorders (etiology)</term><term>Movement Disorders (psychology)</term><term>Neurologic Examination</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (psychology)</term><term>Psychiatric Status Rating Scales</term><term>Quality of Life</term><term>Questionnaires</term><term>Retrospective Studies</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Movement Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Follow-Up Studies</term><term>Health Status Indicators</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination</term><term>Psychiatric Status Rating Scales</term><term>Quality of Life</term><term>Questionnaires</term><term>Retrospective Studies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The impact of motor complications of Parkinson's disease (PD), especially levodopa-induced dyskinesias, on quality of life (QL) was studied in 143 patients with PD. All were evaluated on the Hoehn and Yahr (H&Y) scale, and the Motor part of the Unified Parkinson's Disease Rating Scale (UPDRS). Motor complications were analyzed using the UPDRS Parts IV(A) and IV(B) and the Abnormal Involuntary Movement Scale. A specific Parkinson's disease quality of life questionnaire (39-item version, PDQ-39) was used. Motor complications significantly worsened the PDQ-39 Summary Index (PDQ-SI) of patients with PD. The dimensions of Mobility, Activities of Daily Living, Stigma, and Communication were the most strongly affected. "Peak dose" dyskinesia decreased Mobility, Emotional Well-Being, and Cognition, whereas biphasic dyskinesia affected Mobility, Stigma, Communication, and Activities of Daily Living. Morning akinesia, end-of-dose fluctuations, and "unpredictable offs" decreased QL on the dimensions of Mobility, Activities of Daily Living, Stigma, and Communication. Nocturnal akinesia led to a deterioration of all dimensions of the PDQ-39. Thus, motor complications and especially nocturnal akinesia and biphasic dyskinesias worsened the QL of PD patients.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15384126</PMID><DateCreated><Year>2005</Year><Month>02</Month><Day>22</Day></DateCreated><DateCompleted><Year>2005</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Impact of the motor complications of Parkinson's disease on the quality of life.</ArticleTitle><Pagination><MedlinePgn>224-30</MedlinePgn></Pagination><Abstract><AbstractText>The impact of motor complications of Parkinson's disease (PD), especially levodopa-induced dyskinesias, on quality of life (QL) was studied in 143 patients with PD. All were evaluated on the Hoehn and Yahr (H&Y) scale, and the Motor part of the Unified Parkinson's Disease Rating Scale (UPDRS). Motor complications were analyzed using the UPDRS Parts IV(A) and IV(B) and the Abnormal Involuntary Movement Scale. A specific Parkinson's disease quality of life questionnaire (39-item version, PDQ-39) was used. Motor complications significantly worsened the PDQ-39 Summary Index (PDQ-SI) of patients with PD. The dimensions of Mobility, Activities of Daily Living, Stigma, and Communication were the most strongly affected. "Peak dose" dyskinesia decreased Mobility, Emotional Well-Being, and Cognition, whereas biphasic dyskinesia affected Mobility, Stigma, Communication, and Activities of Daily Living. Morning akinesia, end-of-dose fluctuations, and "unpredictable offs" decreased QL on the dimensions of Mobility, Activities of Daily Living, Stigma, and Communication. Nocturnal akinesia led to a deterioration of all dimensions of the PDQ-39. Thus, motor complications and especially nocturnal akinesia and biphasic dyskinesias worsened the QL of PD patients.</AbstractText><CopyrightInformation>Copyright 2004 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chapuis</LastName><ForeName>Stéphane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service de Neurologie, Centre Hospitalier Vichy, France. stephane.chapuis@ch-vichy.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ouchchane</LastName><ForeName>Lemlih</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Metz</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Gerbaud</LastName><ForeName>Laurent</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Durif</LastName><ForeName>Franck</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006305">Health Status Indicators</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009069">Movement Disorders</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000523">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011569">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D011788">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>9</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>4</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>9</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15384126</ArticleId><ArticleId IdType="doi">10.1002/mds.20279</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country></list><tree><noCountry><name sortKey="Durif, Franck" sort="Durif, Franck" uniqKey="Durif F" first="Franck" last="Durif">Franck Durif</name><name sortKey="Gerbaud, Laurent" sort="Gerbaud, Laurent" uniqKey="Gerbaud L" first="Laurent" last="Gerbaud">Laurent Gerbaud</name><name sortKey="Metz, Olivier" sort="Metz, Olivier" uniqKey="Metz O" first="Olivier" last="Metz">Olivier Metz</name><name sortKey="Ouchchane, Lemlih" sort="Ouchchane, Lemlih" uniqKey="Ouchchane L" first="Lemlih" last="Ouchchane">Lemlih Ouchchane</name></noCountry><country name="France"><noRegion><name sortKey="Chapuis, Stephane" sort="Chapuis, Stephane" uniqKey="Chapuis S" first="Stéphane" last="Chapuis">Stéphane Chapuis</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F59 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000F59 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:15384126
|texte= Impact of the motor complications of Parkinson's disease on the quality of life.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:15384126" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |